Rapid Evaluation in Whole Blood Culture of Regimens for XDR-TB Containing PNU-100480 (Sutezolid), TMC207, PA-824, SQ109, and Pyrazinamide

• Robert S. Wallis ,

  * E-mail: robert.wallis@pfizer.com

  Affiliation Pfizer, Groton, Connecticut, United States of America

  ⨯
• Wesley Jakubiec,

  Affiliation VA Connecticut Healthcare, West Haven, Connecticut, United States of America

  ⨯
• Mark Mitton-Fry,

  Affiliation Pfizer, Groton, Connecticut, United States of America

  ⨯
• Lynn Ladutko,

  Affiliation VA Connecticut Healthcare, West Haven, Connecticut, United States of America

  ⨯
• Sheldon Campbell,

  Affiliations VA Connecticut Healthcare, West Haven, Connecticut, United States of America, Yale University, New Haven, Connecticut, United States of America

  ⨯
• Darcy Paige,

  Affiliation Pfizer, Groton, Connecticut, United States of America

  ⨯
• Annette Silvia,

  Affiliation Pfizer, Groton, Connecticut, United States of America

  ⨯
• Paul F. Miller

  Affiliation Pfizer, Groton, Connecticut, United States of America

  ⨯